Collaborative Pediatric Bone Tumor Program to Improve Access to Specialized Care: An Initiative by the Lebanese Children’s Oncology Group
Authors:
Open Access
- 1 February 2017
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Global Oncology
- Vol. 3 (1) , 23-30
Abstract
Background: Children with malignant bone tumors have average 5-year survival rates of 60% to 70% with current multimodality therapy. Local control modalities aimed at preserving function greatly influence the quality of life of long-term survivors. In developing countries, the limited availability of multidisciplinary care and limited expertise in specialized surgery and pediatric radiation therapy, as well as financial cost, all form barriers to achieving optimal outcomes in this population. Methods: We describe the establishment of a collaborative pediatric bone tumor program among a group of pediatric oncologists in Lebanon and Syria. This program provides access to specialized local control at a tertiary children’s cancer center to pediatric patients with newly diagnosed bone tumors at participating sites. Central review of pathology, staging, and treatment planning is performed in a multidisciplinary tumor board setting. Patients receive chemotherapy at their respective centers on a unified treatment plan. Surgery and/or radiation therapy are performed centrally by specialized staff at the children’s cancer center. Cost barriers were resolved through a program development initiative led by St Jude Children’s Research Hospital. Once program feasibility was achieved, the Children’s Cancer Center of Lebanon Foundation, via fundraising efforts, provided continuation of program-directed funding. Results: Findings over a 3-year period showed the feasibility of this project, with timely local control and protocol adherence at eight collaborating centers. We report success in providing standard-of-care multidisciplinary therapy to this patient population with complex needs and financially challenging surgical procedures. Conclusion: This initiative can serve as a model, noting that facilitating access to specialized multidisciplinary care, resolution of financial barriers, and close administrative coordination all greatly contributed to the success of the program.Keywords
This publication has 17 references indexed in Scilit:
- Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled TrialJournal of Clinical Oncology, 2015
- EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatmentAnnals of Oncology, 2014
- Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2014
- Pediatric Oncology as the Next Global Child Health Priority: The Need for National Childhood Cancer Strategies in Low- and Middle-Income CountriesPLOS Medicine, 2014
- Sustaining innovation and improvement in the treatment of childhood cancer: lessons from high-income countriesThe Lancet Oncology, 2013
- Randomized Controlled Trial of Interval-Compressed Chemotherapy for the Treatment of Localized Ewing Sarcoma: A Report From the Children's Oncology GroupJournal of Clinical Oncology, 2012
- Common Musculoskeletal Tumors of Childhood and AdolescenceMayo Clinic Proceedings, 2012
- Chemotherapeutic adjuvant treatment for osteosarcoma: Where do we stand?European Journal of Cancer, 2011
- Seven‐year experience of using Repiphysis® expandable prosthesis in children with bone tumorsPediatric Blood & Cancer, 2010
- Limb salvage surgery for children and adolescents with malignant bone tumors in a developing countryPediatric Blood & Cancer, 2008